FOLLOWUS
Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)
Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)
- 中国结合医学杂志（英文版） 2007年13卷第2期 页码：120-124
- Affiliations：
1. Department of TCM, The First Affiliated Hospital of the General Hospital of PLA,Beijing,China
2. Dongzhimen Hospital Affiliated to Beijing University of TCM,China
3. Jiangsu Provincial Hospital of TCM,China
4. Department of Pharmaceutics, The First Affiliated Hospital of the General Hospital of PLA,China
- Author bio：
- Funds：Supported by The First Affiliated Hospital of the General Hospital of PLA (No. ZZ2004020)
DOI：10.1007/s11655-007-0120-y
中图分类号：纸质出版日期：2007，
Scan for full text
Qian, Lq., Pei, Xh., Xu, Zy. et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)., Chin. J Integ. Med. 13, 120–124 (2007). https://doi.org/10.1007/s11655-007-0120-y
Qian Li-qi, Pei Xiao-hua, Xu Zhi-yin, et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)[J]. Chinese Journal of Integrative Medicine, 2007,13(2):120-124.
Qian, Lq., Pei, Xh., Xu, Zy. et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)., Chin. J Integ. Med. 13, 120–124 (2007). https://doi.org/10.1007/s11655-007-0120-y DOI：
Qian Li-qi, Pei Xiao-hua, Xu Zhi-yin, et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)[J]. Chinese Journal of Integrative Medicine, 2007,13(2):120-124. DOI： 10.1007/s11655-007-0120-y.
摘要
To explore the efficacy and mechanism of Lirukang Granule (利乳康颗粒
LRKG) in treating hyperplasia of mammary gland (HMG). One hundred patients with HMG were randomly assigned to two groups
50 in each group. The patients in the treated group were orally administered with LRKG thrice a day
one package each time
and those in the control group were given orally Rukuaixiao Tablet (乳块消
RKX) thrice a day
4 tablets each time. The therapeutic course for both groups was 4 months. The clinical efficacy
pain alleviating rate
as well as changes of local sign and symptom scores were observed before and after treatment. The changes of serum estradiol (E2)
progesterone (P)
testosterone (T)
follicle stimulating hormone (FSH)
luteinizing hormone (LH) and prolactin (PRL) in some randomly selected patients (24 patients in the treated group and 24 in the control group) before and after treatment were measured with radioimmunoassay. The total clinical efficacy in the treated group was superior to that in the control group
significant difference was shown between the two groups (P < 0.01). The cure-effective rate and total effective rate in the treated group were 70.0% and 88.0% respectively
significantly higher than those in the control group (38.0% and 64.0%) respectively (P < 0.01)
and the pain alleviating rate in the treated group was also significantly higher in the former than that in the latter (88.0% vs 64.0%
P < 0.05). Moreover
the treated group showed obvious superiority in improving the patients’ symptom and sign scores (P < 0.01)
and abnormalities of gonadal hormone as compared with the respective items in the control group (P < 0.01). LRKG has good efficacy in the treatment of HMG
and its mechanism may be related to the regulation on endocrine and immune function.
Abstract
To explore the efficacy and mechanism of Lirukang Granule (利乳康颗粒
LRKG) in treating hyperplasia of mammary gland (HMG). One hundred patients with HMG were randomly assigned to two groups
50 in each group. The patients in the treated group were orally administered with LRKG thrice a day
one package each time
and those in the control group were given orally Rukuaixiao Tablet (乳块消
RKX) thrice a day
4 tablets each time. The therapeutic course for both groups was 4 months. The clinical efficacy
pain alleviating rate
as well as changes of local sign and symptom scores were observed before and after treatment. The changes of serum estradiol (E2)
progesterone (P)
testosterone (T)
follicle stimulating hormone (FSH)
luteinizing hormone (LH) and prolactin (PRL) in some randomly selected patients (24 patients in the treated group and 24 in the control group) before and after treatment were measured with radioimmunoassay. The total clinical efficacy in the treated group was superior to that in the control group
significant difference was shown between the two groups (P < 0.01). The cure-effective rate and total effective rate in the treated group were 70.0% and 88.0% respectively
significantly higher than those in the control group (38.0% and 64.0%) respectively (P < 0.01)
and the pain alleviating rate in the treated group was also significantly higher in the former than that in the latter (88.0% vs 64.0%
P < 0.05). Moreover
the treated group showed obvious superiority in improving the patients’ symptom and sign scores (P < 0.01)
and abnormalities of gonadal hormone as compared with the respective items in the control group (P < 0.01). LRKG has good efficacy in the treatment of HMG
and its mechanism may be related to the regulation on endocrine and immune function.
关键词
hyperplasia of mammary glandtraditional Chinese medicinal therapyLirukang Granule
Keywords
hyperplasia of mammary glandtraditional Chinese medicinal therapyLirukang Granule
references
Hu SF, Chen HF. Survey on risk factors of mammary cancer in patients with mammary hyperplasia and their correlation with Chinese medical syndromes. Shanghai J Tradit Chin Med 2004; 38(5): 10–11.
Li JY, Huang F, Li DX, et al. Immunological mechanism of apoptosis induced by Chinese herbal medicine. Chin J Basic Med Tradit Chin Med 2001; 7(2): 20–22.
Liang W. Progress on the immuno-regulatory action of Chinese herbal medicine. Modern Med Health 2005; 21(6) 674–676.
Cao Y, Nie H, Zhang D, et al. Experimental study on the tumor inhibitory and efficacy enhancing effect of Bushen Huayu Jiedu recipe on sarcoma S180 of mice. Chin J Pract Chin Modern Med 2004; 4(17): 2341–2342.
He L, Xu YH, Liu YP. Thinking path of experimental study on the immuno-regulatory action of Chinese compounds for anti-tumor. J Chin Med Pharm 2003; 31(5): 16–17.
Qian LQ, Pan C, Feng ZQ, et al. Effect of Lirukang Liquid on morphology of mammary gland, uterus and ovary of models with hyperplasia of mammary glands. J Nangjing Univ Tradit Chin Med (Nat Sci) 2005; 21(4): 255–257.
Qian LQ, Pei XH, Chen RM, et al. Effect of Lirukang Oral Liquid on neurotransmitters and estrogen in rats with hyperplasia of mammary gland. Chin J Integr Med 2004; 9(2): 131–133.
Qan LQ, Pei XH, Xu ZY. Effect of Lirukang oral liquid on integral condition of model of mammary gland hyperplasia. J Nangjing Univ Tradit Chin Med (Nat Sci) 2002; 18(3): 167–168.
Ministry of Health, P. R. China. Guiding Principle of Clinical Research on New Drugs of TCM. Vol 3. 1997: 50–51.
Wang MY, editor. Hormone Biochemistry. Beijing: People’s Medical Publishing House, 1987: 35–36.
Que HF, Que ZF, Deng XA. Correlative study on neuroendorine and the typing of mastohyperplasia according to syndrome differentiation. Chin Arch Chin Med 2001; 19(2): 98–99.
Zhou QL, Bao HY, Zhang YW, et al. Studies on therapeutic effect of antler on cystic hyperplasia of breast in the rat II: Studies on mechanism of inhibiting cystichyperplasia. Pharmacol Clin Chin Materia Med 1998; 14(3): 23–25.
Zhang JS, Wang SX. Effect of curcumin on proliferation of human cancer cell lines of BCH, MGC-803 and BEL-7402. Chin J Inform Tradit Chin Med 2001; 8(1): 40–41.
Wang Y, Ma AL, Zhang HZ, et al. Experimental studies on the anitumor effect of oyster extract. Chin J Marine Drugs 1997; 16(1): 18–22.
Wen L, Yuan J. Actions of Lijiang pleione bulbocodioides. Chin J Etho Med Ethnopharm 2003; (3): 180–181.
0
浏览量
363
Downloads
14
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
